Larimar Therapeutics Inc (LRMR)

Larimar Therapeutics Shares Drop Following Clinical Update and Regulatory Filing (LRMR)June 29, 2026 10:00 AM
IH Market News Larimar Therapeutics (NASDAQ:LRMR) shares declined 17% on Monday after the company released new data from its ongoing open-label study and confirmed the submission of the first section of its rolling Biologics License Application (BLA) seeking accelerated approval for nomlabofusp as a treatment for Friedreich’s ataxia. The biotechnology company said the initial BLA module has been submitted to the U.S. Food and Drug Administration, with the remaining sections scheduled for submission during the second half of 2026. The filing follows discussions with the FDA during a Type B multidisciplinary pre-BLA meeting. Long-Term Study Shows Sustained Frataxin Levels Updated results from the ongoing open-label trial demonstrated that once-daily treatment with nomlabofusp increased and maintained skin frataxin levels after one year and 18 months of therapy. All nine participants with one-year follow-up data achieved and sustained frataxin levels above 50% of the average observed in healthy volunteers, reaching levels comparable with asymptomatic heterozygous carriers. The study has enrolled 43 adolescent and adult patients who received at least one dose of nomlabofusp, with 22 participants still actively receiving treatment as of June 2026. Nearly half of the study population (49%) was non-ambulatory when treatment began. Phase 3 Study Planned for Later This Year Patients receiving nomlabofusp also demonstrated directional improvements across several clinical outcome measures after one year compared with a natural history reference population. Among six participants who were non-ambulatory at baseline, one regained the ability to walk after one year of treatment, while none of the seven ambulatory participants experienced progression to non-ambulatory status during the same period. The company reported anaphylaxis in 10 of the 43 treated patients, with nine of those individuals having previously received nomlabofusp in an earlier clinical study. Among the 11 participants without prior exposure, one experienced anaphylaxis. Larimar added that long-term treatment has generally been well tolerated, with more than 10,000 doses administered during the open-label study. The company expects to enrol the first patient in its global confirmatory Phase 3 trial during the third quarter of 2026 and continues to target a potential commercial launch in mid-2027, subject to regulatory approval. Larimar Therapeutics stock priceThe post Larimar Therapeutics Shares Drop Following Clinical Update and Regulatory Filing (LRMR) appeared first on US Editors. Original: Larimar Therapeutics Shares Drop Following Clinical Update and Regulatory Filing (LRMR)

LRMR quietly building and the market hasn’t really priced in the upside yet imo. These are the type that move hard once liquidity shows up, i’m watching for momentum shift.

lrmr............................................https://stockcharts.com/sc3/ui/?s=LRMR&p=w&b=5&g=0&id=p86431144783

LRMR above $9 momentarily

LRMR under $10

LRMR under $10

LRMR new 52 week high

LRMR new 52=week high

$LRMR - Announced that the FDA has cleared the Company’s four-week, placebo-controlled, Phase 2 dose exploration trial of CTI-1601
👆Up 8% Pre-Market/ Current Price $3,40

could probably get through approval on just 25 mg if they are going to approve reta

The company said it received feedback from the FDA on information needed to resolve CTI-1601's current clinical hold, as well as a proposed change for a second phase. CTI-1601 is a treatment for Friedreich's ataxia.

Larimer plans to submit a complete response to CTI-1601's clinical hold in the third quarter.

Larimar is also proposing a phase two, four-week dose exploration study in Friedreich's ataxia patients. Friedreich's ataxia is a rare disease that causes progressive nervous system damage and movement problems, usually beginning during childhood.

I voted NO on the 2022 Annual Meeting Vote. I recommend you do the same.

Interesting.

Waking up . But volume should be higher.

LRMR 2Q20 results—6/30/20 cash=$113.7M:

https://www.globenewswire.com/news-release/2020/08/11/2076240/0/en/Larimar-Therapeutics-Reports-Second-Quarter-2020-Operating-and-Financial-Results.html

No CC.

Large chunks are being gobbled
Whales are lurking around?

The company they are merging with looks pretty darn impressive
https://chondrialtherapeutics.com/

Volume!

* * $ZFGN Video Chart 12-26-2019 * *

Link to Video - click here to watch the technical chart video

* * $ZFGN Video Chart 12-24-2019 * *

Link to Video - click here to watch the technical chart video

News: $ZFGN Penny Stocks To Buy Or Sell Before The End Of 2019?

These Penny Stocks Moved Big But Can They Continue Higher Before Next Year? Over the course of the year, plenty of penny stocks have generated significant gains for investors. Even as the year comes to a close, there are some penny stocks that are gaining momentum. It is often said that inve...

Got this from ZFGN - Penny Stocks To Buy Or Sell Before The End Of 2019?

Like I said at .67 cents

* * $ZFGN Video Chart 12-23-2019 * *

Link to Video - click here to watch the technical chart video

Wow...guess they will satisfy the 1dollar minimum nasd requirement with out rs.....
This will be huge when ticker change and merger consummated next month!

Scrap the notice of delisting boys.....

82M cash and 30M OS....sounds fun!

* * $ZFGN Video Chart 12-20-2019 * *

Link to Video - click here to watch the technical chart video

Over a buck soon when ticker change completed....

exactly is great

Probably 3-9 months away still - appears to be a massive over correction and tax loss selling on the merger news. Just a short target at the moment. They will run this in Q1 pre-split to get a much more favorable ratio IMO. Let's see what happens. Lots of cash on hand here at very low burn rate per Q.

The transaction is expected to close in the first half of 2020, subject to approvals by stockholders of each company and other customary closing conditions.

R/Split coming per 8k today

December discounts. With 85 million in cash, a merger, and priced at 67 cents there's no way this doesn't run soon. 35 million O/S.

Ticker change coming...Shorts will get burn if they will not cover or do damage control.
ZFGN has 82M dollars in cash!

The proposed merger will result in a combined publicly traded, clinical-stage biopharmaceutical company operating under a new name, Larimar Therapeutics, Inc.

Shorts covering.. they have to before it gets out of control once the merger is official...

10 day MA live chart huge oversold,safe here now,will recover nice

bought 3k at 6391

Just saw a bunch come through on tape that were vastly different but didn't indicate "out of sequence"...they were either out of sequence or it was a messed up market order. Just odd. This one is clearly under short attack. Volume could squeeze it near term.

ZFGN~~Balance Sheet
Total Cash (mrq) 82.01M
Total Cash Per Share (mrq) 2.19
Total Debt (mrq) 24.35M
Total Debt/Equity (mrq) 40.67
Current Ratio (mrq) 5.11
Book Value Per Share (mrq) 1.60
https://finance.yahoo.com/quote/ZFGN/key-statistics?p=ZFGN

not really. that would mean its been up and down, up and down. this is nothing but down..

...this price action is ALL over the place. Crazy.

man i hope so. just want out even now

$ZFGN in at .70

Short this

will recover but sucks,waste of time

Zafgen and Chondrial Therapeutics will host an investor conference call today, December 18, 2019, at 8:30 a.m.,

Conference Call Information
Zafgen and Chondrial Therapeutics will host an investor conference call today, December 18, 2019, at 8:30 a.m., Eastern Time, to discuss the merger as well as other forward-looking information. Investors and other interested parties may participate by dialing (844) 824-7428 in the United States or (973) 500-2177 outside the United States and referencing conference ID number 5688136. The call will also be webcast live on the Company's website at https://zafgen.gcs-web.com/events-and-presentations. A replay of this conference call will be available beginning at 11:30 a.m. ET on December 18, 2019 through December 25, 2019 by dialing (855) 859-2056 in the United States or (404) 537-3406 outside the United States. To access the replay please provide Conference ID number 5688136.

dont think so

This is done no benefit to this company but ONTX will make you very rich

institutions selling off?

the news is great,why?

fffffffffffffffffff MMS

i guess were screwed